Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Josée Golay"'
Autor:
Giuseppe Gritti, Silvia Ferrari, Federico Lussana, Anna Maria Barbui, Francesco Landi, Monica Rondi, Alessandro Putelli, Francesco Ballardini, Giulia Quaresmini, Muriel Paganessi, Chiara Pavoni, Arianna Ghirardi, Elisa Gotti, Chiara Capelli, Josée Golay, Martino Introna, Alessandro Rambaldi
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/f762c188dbf54df5a16ff6071725f9ad
Autor:
Silvia Zaninelli, Silvia Panna, Sarah Tettamanti, Giusi Melita, Andrea Doni, Francesca D’Autilia, Rut Valgardsdottir, Elisa Gotti, Alessandro Rambaldi, Josée Golay, Martino Introna
Publikováno v:
Antibodies, Vol 13, Iss 3, p 71 (2024)
Strategies to increase the anti-tumor efficacy of cytokine-induced killer cells (CIKs) include genetic modification with chimeric antigen receptors (CARs) or the addition of soluble T-cell engaging bispecific antibodies (BsAbs). Here, CIKs were modif
Externí odkaz:
https://doaj.org/article/2e46ffc25a0e4747b6c5221b2f34f8e8
Autor:
Irene Cattaneo, Sylvie Choblet, Rut Valgardsdottir, Muriel Roth, Annamaria Massafra, Marten Beeg, Marco Gobbi, Martine Duonor-Cerutti, Josée Golay
Publikováno v:
Antibodies, Vol 13, Iss 1, p 15 (2024)
We designed, produced, and purified a novel IgG1-like, bispecific antibody (bsAb) directed against B-cell maturation antigen (BCMA), expressed by multiple myeloma (MM) cells, and an immune checkpoint inhibitor (ICI), PDL1, expressed in the MM microen
Externí odkaz:
https://doaj.org/article/6fa362dcbed34f4f9ee34e7988391880
Autor:
Chiara Capelli, Carolina Cuofano, Chiara Pavoni, Simona Frigerio, Daniela Lisini, Sara Nava, Michele Quaroni, Valentina Colombo, Francesco Galli, Svetlana Bezukladova, Paola Panina-Bordignon, Giuseppe Gaipa, Patrizia Comoli, Giulio Cossu, Gianvito Martino, Andrea Biondi, Martino Introna, Josée Golay
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Advanced Therapy Medicinal Products (ATMPs) based on somatic cells expanded in vitro, with or without genetic modification, is a rapidly growing area of drug development, even more so following the marketing approval of several such products. ATMPs a
Externí odkaz:
https://doaj.org/article/e7e8c018f7064952b7ad32669b4e28f7
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The presence of fucose on IgG1 Asn-297 N-linked glycan is the modification of the human IgG1 Fc structure with the most significant impact on FcɣRIII affinity. It also significantly enhances the efficacy of antibody dependent cellular cytotoxicity (
Externí odkaz:
https://doaj.org/article/462551c3f74843ca8a4aeb1dcad4b5e6
Autor:
Martino Introna, Josée Golay
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Mesenchymal Stromal Cells (MSCs) are fibroblast-like cells of mesodermal origin present in many tissues and which have the potential to differentiate to osteoblasts, adipocytes and chondroblasts. They also have a clear immunosuppressive and tissue re
Externí odkaz:
https://doaj.org/article/123cce905b6940eb81613a1d5e6f658c
Autor:
Josée Golay, Ronald P. Taylor
Publikováno v:
Antibodies, Vol 9, Iss 4, p 58 (2020)
Unconjugated anti-cancer IgG1 monoclonal antibodies (mAbs) activate antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages, and these activities are thought to b
Externí odkaz:
https://doaj.org/article/ce10ef25173042d7b55b8e2593f25340
Autor:
Josée Golay, Alain E. Andrea
Publikováno v:
Antibodies, Vol 9, Iss 2, p 17 (2020)
Therapeutic monoclonal antibodies for the treatment of cancer came of age in 1997, with the approval of anti-CD20 Rituximab. Since then, a wide variety of antibodies have been developed with many different formats and mechanisms of action. Among thes
Externí odkaz:
https://doaj.org/article/1ffb66dbe0fa451191d08fde60bb6b4b
Publikováno v:
Haematologica, Vol 102, Iss 10 (2017)
Externí odkaz:
https://doaj.org/article/eef1cecdfd714a719ca9737068d5ff5d
Autor:
Fabio Da Roit, Patrick J. Engelberts, Ronald P. Taylor, Esther C.W. Breij, Giuseppe Gritti, Alessandro Rambaldi, Martino Introna, Paul W.H.I. Parren, Frank J. Beurskens, Josée Golay
Publikováno v:
Haematologica, Vol 100, Iss 1 (2015)
The novel Bruton tyrosine kinase inhibitor ibrutinib and phosphatidyl-4-5-biphosphate 3-kinase-δ inhibitor idelalisib are promising drugs for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma, either alone or in combinati
Externí odkaz:
https://doaj.org/article/1c94da3a61174fd1bdb1a8cfcd711ad4